Fed’s Powell opens door to potential rate cuts at Jackson Hole
SARASOTA, Fla. - INVO Fertility, Inc. (NASDAQ:IVF), a micro-cap company with a market value of $1.77 million operating in the fertility market, announced Thursday it will implement a 1-for-3 reverse stock split effective July 21, 2025. The announcement comes as the stock has declined over 91% year-to-date, according to InvestingPro data.
The company’s common stock will continue trading on the Nasdaq Capital Market under the same symbol "IVF" but with a new CUSIP number: 44984F708.
Under the terms of the split, every three shares of issued and outstanding common stock will be exchanged for one share, with fractional shares rounded up to the next whole share. Following the split, INVO will have approximately 928,272 shares outstanding, and its authorized shares will be adjusted to 1,388,888.
The primary purpose of the reverse split is to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share for continued listing, according to the company’s press release statement. However, INVO noted that there is no guarantee the action will enable it to meet this requirement.
INVO Fertility operates two INVO Centers in the United States and one in vitro fertilization (IVF) clinic. The company’s business focuses on fertility clinic operations and the distribution of its INVOcell technology, a medical device that allows fertilization and early embryo development to occur within a woman’s body.
In other recent news, INVO Fertility, Inc. has reported several significant developments. The company announced amendments to its securities agreements, allowing the holder of its Series C-2 Convertible Preferred Stock to acquire additional shares, with a total stated value of $1.8 million. INVO Fertility also issued 630 new unregistered Series C-2 Preferred shares and agreed to a 30-day restriction on issuing common stock. At its 2025 annual meeting, INVO Fertility’s stockholders approved key proposals, including the election of board members and the ratification of M&K CPAs PLLC as the independent public accountant for the fiscal year ending December 31, 2025.
Additionally, INVO Fertility received a notice of allowance for a new patent on a modified version of its INVOcell device, extending intellectual property protection through 2040. This patent reflects feedback from embryologists to simplify the device design. The United States Patent and Trademark Office issued the notice for a patent titled "Intravaginal Culture Incubation Container and Method." The company also adjourned its annual stockholder meeting, setting a new date for July 23, 2025, to reconvene virtually.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.